VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.
17-Allylamino-17-demethoxy geldanamycin (17-AAG), an inhibitor of heat shock protein 90 (Hsp90) function, is being developed as antitumor drug in patients with breast cancer. However, water-insolubility and hepatotoxicity limit its use. The purpose of this study was to begin to address these issues by determining whether 17-AAG can be formulated in long-circulating (PEGylated), biocompatible and biodegradable sterically stabilized phospholipid nanomicelles (SSM) to which vasoactive intestinal peptide (VIP) was grafted as an active targeting moiety and, if so, whether these nanomicelles are cytotoxic to MCF-7 human breast cancer cells. We found that particle size of 17-AAG loaded in VIP surface-grafted SSM was 16+/-1 nm and drug content was 97+/-2% (300 microg/ml). Cytotoxicity of 17-AAG loaded in VIP surface-grafted SSM to MCF-7 cells was significantly higher than that of 17-AAG loaded in non-targeted SSM (p<0.05) and similar to that of 17-AAG dissolved in dimethylsulfoxide. Collectively, these data demonstrate that 17-AAG is solubilized at therapeutically relevant concentrations in actively targeted VIP surface-grafted SSM. Cytotoxicity of these nanomicelles to MCF-7 cells is retained implying high affinity VIP receptors overexpressed on these cells mediate, in part, their intracellular uptake thereby amplifying drug potency. We propose that 17-AAG loaded in VIP surface-grafted SSM should be further developed as actively targeted nanomedicine for breast cancer.
Onyüksel
Hayat
H
Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL 60612-4325, USA.
Mohanty
Prem S
PS
Rubinstein
Israel
I
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D016227:Benzoquinones / Q000008:administration & dosage* / Q000737:chemistry; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D005260:Female; D005786:Gene Expression Regulation; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D047029:Lactams, Macrocyclic / Q000008:administration & dosage* / Q000737:chemistry; D008823:Micelles; D010316:Particle Size; D012995:Solubility; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D008823:Micelles; D014660:Vasoactive Intestinal Peptide; C112765:tanespimycin
J Antibiot (Tokyo). 1970 Sep;23(9):442-7
5459626
Cancer Res. 1988 Sep 15;48(18):5079-83
2842044
Nanomedicine. 2005 Mar;1(1):77-84
17292061
Chem Biol Interact. 2008 Jan 30;171(2):190-4
17499651
Langmuir. 2005 Apr 12;21(8):3279-90
15807565
Int J Cancer. 1992 Jun 19;51(4):613-9
1601523
J Clin Oncol. 2007 Dec 1;25(34):5410-7
18048823
Hum Exp Toxicol. 1996 Sep;15(9):751-85
8880211
Anticancer Drugs. 2004 Aug;15(7):651-62
15269596
Cell. 2000 Jan 7;100(1):57-70
10647931
J Pharm Sci. 2004 Oct;93(10):2476-87
15349957
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324-8
8078881
Ann N Y Acad Sci. 1996 Dec 26;805:753-9
8993473
Clin Cancer Res. 2007 Mar 15;13(6):1789-93
17363534
Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15
8102012
J Control Release. 2003 Aug 28;91(1-2):123-33
12932644
Pharm Res. 2003 Feb;20(2):297-302
12636171
Clin Cancer Res. 2007 Mar 15;13(6):1775-82
17363532
Cancer Lett. 2004 Apr 8;206(2):149-57
15013520
Expert Opin Biol Ther. 2002 Jan;2(1):3-24
11772336
J Control Release. 2001 Jul 6;74(1-3):129-34
11489489
Breast Dis. 2002;15:53-60
15687645
Curr Pharm Des. 2001 Jan;7(2):89-111
11172702
Nat Protoc. 2006;1(3):1112-6
17406391